Twist Bioscience (TWST) to Release Earnings on Monday

Key Points

• Twist Bioscience will report Q2 2026 results before the market opens on Monday, May 4 at 8:00 AM ET; analysts expect EPS of ($0.54) and revenue of $107.645 million.
• In the prior quarter the company missed EPS (reported ($0.50) vs. consensus ($0.48)) while revenue rose 16.9% year‑over‑year to $103.7 million, and analysts project about ($2) EPS for the current and next fiscal year.
• Insiders have been net sellers recently — including CEO Emily Leproust selling 8,061 shares — with 62,720 shares (~$3.23M) sold in the last 90 days; the stock has a market cap of $3.74 billion and a 12‑month range of $23.30–$66.06.

Twist Bioscience (NASDAQ:TWST - Get Free Report) is expected to be releasing its Q2 2026 results before the market opens on Monday, May 4th. Analysts expect Twist Bioscience to post earnings of ($0.54) per share and revenue of $107.6450 million for the quarter. Individuals can check the company's upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, May 4, 2026 at 8:00 AM ET.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The company had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. The company's revenue was up 16.9% compared to the same quarter last year. On average, analysts expect Twist Bioscience to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Twist Bioscience Price Performance

NASDAQ TWST opened at $60.94 on Monday. Twist Bioscience has a 12 month low of $23.30 and a 12 month high of $66.06. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37. The firm has a market capitalization of $3.74 billion, a PE ratio of -47.61 and a beta of 2.20. The company's 50 day simple moving average is $49.95 and its 200 day simple moving average is $40.28.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 8,061 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $65.29, for a total value of $526,302.69. Following the transaction, the chief executive officer owned 858,887 shares in the company, valued at approximately $56,076,732.23. The trade was a 0.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Dennis Cho sold 5,000 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $49.93, for a total transaction of $249,650.00. Following the completion of the transaction, the insider owned 138,581 shares in the company, valued at approximately $6,919,349.33. This trade represents a 3.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 62,720 shares of company stock valued at $3,234,686 in the last 90 days. 3.08% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Mercer Global Advisors Inc. ADV acquired a new position in Twist Bioscience in the fourth quarter worth approximately $242,000. Align Financial LLC acquired a new position in Twist Bioscience in the 4th quarter worth approximately $203,000. Stifel Financial Corp boosted its stake in Twist Bioscience by 3.6% in the 4th quarter. Stifel Financial Corp now owns 7,769 shares of the company's stock worth $246,000 after purchasing an additional 271 shares during the period. Van ECK Associates Corp boosted its stake in Twist Bioscience by 99.2% in the 4th quarter. Van ECK Associates Corp now owns 2,076 shares of the company's stock worth $66,000 after purchasing an additional 1,034 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new position in Twist Bioscience in the 4th quarter worth approximately $246,000.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Robert W. Baird set a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday, February 3rd. TD Cowen reiterated a "buy" rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Guggenheim raised their price objective on shares of Twist Bioscience from $50.00 to $55.00 and gave the company a "buy" rating in a research note on Monday, March 30th. Barclays raised their price objective on shares of Twist Bioscience from $50.00 to $55.00 and gave the company an "overweight" rating in a research note on Tuesday, April 14th. Finally, Evercore raised their price objective on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an "outperform" rating in a research note on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $47.13.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.